{"name":"Kathleen Dungan","slug":"kathleen-dungan","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Aspart fixed dose","genericName":"Aspart fixed dose","slug":"aspart-fixed-dose","indication":"Other","status":"marketed"},{"name":"Subcutaneous insulin","genericName":"Subcutaneous insulin","slug":"subcutaneous-insulin","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Aspart fixed dose","genericName":"Aspart fixed dose","slug":"aspart-fixed-dose","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Subcutaneous insulin","genericName":"Subcutaneous insulin","slug":"subcutaneous-insulin","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE52bjY2akM1bkNRd2gxZ195cnJid0djWW9PTjNEQzE1U1pCSGdybTg4bmVSaVZHX0I5YXhPekdEWWN6SnRHZUlxbWppckFZZkdjZFBXNUROeUJSeGVGaDFfTg?oc=5","date":"2019-06-11","type":"regulatory","source":"NEJM","summary":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes - NEJM","headline":"Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}